Prognostic relevance of number and bilaterality of positive surgical margins after radical prostatectomy.
OBJECTIVE
Positive surgical margin (PSM) status following radical prostatectomy (RP) is a well-established prognostic factor. The aim of the present study is to evaluate whether number of PSMs or bilaterality of PSMs might have prognostic significance for biochemical recurrence (BCR) in the population with a PSM status following RP.


METHODS
We evaluated 1,395 RP pathology reports from our center between 1980 and 2006. All patients who underwent (neo)-adjuvant therapy were excluded, leaving a cohort of 1,009 patients, with 249 (24.7%) subjects having a PSM at RP of whom 29.4% had multiple PSMs (≥ 2 sites), while 13.6% had bilateral PSMs. Median follow-up was 40 months (range 0-258 months). We used BCR-free survival as the primary study outcome. BCR was defined as any rise in PSA above or equal to 0.2 ng/ml.


RESULTS
Of patients with a PSM status, 41% (95% CI: 33-49%) developed BCR within 5 years, compared to 12% (95% CI: 9-15%) in the population without a PSM. Multivariable analysis identified PSA at diagnosis and RP Gleason score as independent predictive factors for BCR. Increasing number and/or bilaterality of PSM did not lead to significant higher rates of BCR.


CONCLUSIONS
In patients with a PSM, the number of positive sites or bilaterality of PSM status does not add prognostic information for risk of BCR. Survival curve slopes were different for patients with bilateral PSM, showing a significant tendency to progress to BCR earlier during follow-up than patients with unilateral PSM.
Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands.
Diederik M
DM
Somford
Inge M
IM
van Oort
Jean-Pierre
JP
Cosyns
J Alfred
JA
Witjes
Lambertus A L M
LA
Kiemeney
Bertrand
B
Tombal
D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D018365:Neoplasm, Residual / Q000517:prevention & control*; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology* / Q000601:surgery*; D012189:Retrospective Studies
D017430:Prostate-Specific Antigen
J Urol. 2005 Sep;174(3):903-7
16093984
Urology. 1996 Jul;48(1):80-90
8693658
J Urol. 1994 Nov;152(5 Pt 2):1850-7
7523733
Urology. 2005 Dec;66(6):1245-50
16360451
J Natl Cancer Inst. 2008 Aug 20;100(16):1144-54
18695132
J Clin Oncol. 2007 Sep 20;25(27):4178-86
17878474
J Urol. 1997 Oct;158(4):1452-6
9302141
J Urol. 2000 Apr;163(4):1171-7; quiz 1295
10737489
Arch Pathol Lab Med. 2000 Jul;124(7):995-1000
10888774
J Clin Oncol. 1999 May;17(5):1499-507
10334537
J Urol. 2002 Jun;167(6):2453-6
11992056
Urology. 2008 Feb;71(2):308-12
18308109
J Urol. 2006 Jan;175(1):140-4; discussion 144-5
16406892
J Urol. 2008 May;179(5):1791-6; discussion 1796
18343426
JAMA. 1998 Sep 16;280(11):969-74
9749478
Eur Urol. 2006 Aug;50(2):258-65
16413660
Urology. 1995 May;45(5):831-8
7538245
J Urol. 2001 Jan;165(1):126-9
11125380
BJU Int. 2008 Nov;102(10):1413-8
18537951
J Urol. 2010 Oct;184(4):1341-6
20723925
Mod Pathol. 2008 Sep;21(9):1095-100
18500264
Cancer. 1998 Mar 1;82(5):902-8
9486580
Lancet. 2005 Aug 13-19;366(9485):572-8
16099293
Urology. 1997 Nov;50(5):733-9
9372884
Eur Urol. 2009 Jan;55(1):87-99
18838211
Cancer. 2002 Sep 15;95(6):1215-9
12216087
Urol Clin North Am. 1996 Nov;23(4):651-63
8948418